Table 1.
GDC-0449 lowers the IC-50 of erlotinib/cisplatin in A549M / H1299 cells
| Cell Line | Standard Therapy |
IC50 (μM) |
% Decrease in IC50 | |
|---|---|---|---|---|
| Without GDC | With GDC | |||
| A549 |
Erlotinib |
11.56 |
11.27 |
2.51 |
| Cisplatin |
4.11 |
4.04 |
1.70 |
|
| A549M |
Erlotinib |
43.64 |
15.76 |
63.89 |
| Cisplatin |
36.16 |
9.64 |
73.34 |
|
| H1299 | Erlotinib |
10.57 |
7.20 |
31.90 |
| Cisplatin | 12.15 | 4.19 | 65.56 | |
Cells were pre-treated with 20nM GDC-0449 (GDC) for 72 h or vehicle control, prior to treatments with increasing doses of erlotinib or cisplatin for 72 h.